Neurological Sciences

, Volume 29, Supplement 2, pp 233–234

Cyclophosphamide-based combination therapies for autoimmunity

  • Paola Perini
  • Massimiliano Calabrese
  • Luciano Rinaldi
  • Paolo Gallo
Multiple Sclerosis: The Management of Non-Responders

Abstract

Immunomodulatory agent (IMA)-unresponsive multiple sclerosis (MS) can quickly evolve to a dramatic and irreversible disability. Treating these patients with appropriate immunosuppressive therapies can be a chance to arrest disease activity and progression. Cyclophosphamide (Cyc)-based intense immunosuppression has been successfully used to treat rapidly deteriorating, IMA-refractory MS patients. Therapeutic protocols combining Cyc and interferon beta (IFNβ) have also been successfully applied to treat IFNβ-unresponsive MS. The association of Cyc with other immunomodulatory drugs or monoclonal antibodies is currently being investigated in clinical trials aimed at treating severe forms of autoimmune diseases.

Keywords

Cyclophosphamide Combination therapy Multiple sclerosis Autoimmunity 

References

  1. 1.
    Kovarsky J (1983) Clinical pharmacology and toxicology of cyclophosphamide: emphasis on use in rheumatic diseases. Semin Arthritis Rheum 12:359–372PubMedCrossRefGoogle Scholar
  2. 2.
    Boumpas DT, Austin HA 3rd, Fessler BJ et al (1995) Systemic lupus erythematosus: emerging concepts. Part 1: renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic disease. Ann Intern Med 122:940–950PubMedGoogle Scholar
  3. 3.
    Brannagan TH 3rd, Pradhan A, Heiman-Patterson T et al (2002) Highdose cyclophosphamide without stem-cell rescue for refractory CIDP. Neurology 58:1856–1858PubMedGoogle Scholar
  4. 4.
    Gauthier SA, Weiner HL (2005) Cyclophosphamide therapy for MS. Int MS J 12:52–58PubMedGoogle Scholar
  5. 5.
    Perini P, Calabrese M, Rinaldi L, Gallo P (2007) The safety profile of cyclophosphamide in multiple sclerosis therapy. Expert Opin Drug Saf 6:183–190PubMedCrossRefGoogle Scholar
  6. 6.
    Comabella M, Balashov K, Issazadeh et al (1998) Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy. J Clin Invest 102:671–678PubMedCrossRefGoogle Scholar
  7. 7.
    Smith DR, Balashov KE, Hafler DA et al (1997) Immune deviation following pulse cyclophosphamide/methylprednisolone treatment of multiple sclerosis: increased interleukin-4 production and associated eosinophilia. Ann Neurol 42:313–318PubMedCrossRefGoogle Scholar
  8. 8.
    Balashov KE, Smith DR, Khoury SJ et al (1997) Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand. Proc Natl Acad Sci U S A 94:599–603PubMedCrossRefGoogle Scholar
  9. 9.
    Weiner HL (2004) Immunosuppressive treatment in multiple sclerosis. J Neurol Sci 223:1–11PubMedCrossRefGoogle Scholar
  10. 10.
    Smith DR, Weinstock-Guttman B, Cohen JA et al (2005) A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon beta. Mult Scler 11:573–582PubMedCrossRefGoogle Scholar
  11. 11.
    Patti F, Reggio E, Palermo F et al (2004) Stabilization of rapidly worsening multiple sclerosis for 36 months in patients treated with interferon beta plus cyclophosphamide followed by interferon beta. J Neurol 251:1502–1506PubMedCrossRefGoogle Scholar
  12. 12.
    Patti F, Cataldi ML, Nicoletti F et al (2001) Combination of cyclophosphamide and interferon-beta halts progression in patients with rapidly transitional multiple sclerosis. J Neurol Neurosurg Psychiatry 71:404–407PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2008

Authors and Affiliations

  • Paola Perini
    • 1
  • Massimiliano Calabrese
    • 1
  • Luciano Rinaldi
    • 1
  • Paolo Gallo
    • 1
  1. 1.Multiple Sclerosis Centre-Veneto Region, Department of NeuroscienceUniversity HospitalPadovaItaly

Personalised recommendations